Recombinant Human IL-12
Interleukin-12 (IL-12), also known as natural killer cell stimulatory factor (NKSF) or cytotoxic lymphocyte maturation factor (CLMF), is a pleiotropic cytokine originally identified in the medium of activated human B lymphoblastoid cell lines [1]. The p40 subunit of IL-12 has been shown to have extensive amino acid sequence homology to the extracellular domain of the human IL-6 receptor while the p35 subunit shows distant but significant sequence similarity to IL-6, G-CSF, and chicken MGF [2, 3]. These observations have led to the suggestion that IL-12 might have evolved from a cytokine/soluble receptor complex. Human and murine IL-12 share 70% and 60% amino acid sequence homology in their p40 and p35 subunits, respectively. IL-12 apparently shows species specificity with human IL-12 reportedly showing minimal activity in the murine system. IL-12 is produced by macrophages and B lymphocytes and has been shown to have multiple effects on T cells and natural killer (NK) cells [4]. These effects include inducing production of IFN-r and TNF by resting and activated T and NK cells, synergizing with other IFN-gamma inducers at both the transcriptional and post-transcriptional levels. This interaction induces IFN-gamma gene expression, enhancing the cytotoxic activity of resting NK and T cells, inducing and synergizing with IL-2 in the generation of lymphokine-activated killer (LAK) cells, acting as a co-mitogen to stimulate proliferation of resting T cells, and inducing proliferation of activated T and NK cells [5]. Current evidence indicates that IL-12, produced by macrophages in response to infectious agents, is a central mediator of the cell-mediated immune response by its actions on the development, proliferation, and activities of TH1 cells. In its role as the initiator of cell-mediated immunity, it has been suggested that IL-12 has therapeutic potential as a stimulator of cell-mediated immune responses to microbial pathogens, metastatic cancers, and viral infections such as AIDS.
Reference
[1]. Gubler, U. et al. (1991) Proc. Natl. Acad. Sci. 88:4143.
[2]. Gearing, D. et al. (1991) Cell 66:9.
[3]. Merberg, D. et al. (1992) Immunology Today 13:78.
[4]. Wolf, S.F. et al. (1991) Journal of Immunology 146:3074.
[5]. Airoldi, I. et al. (2000) Journal of Immunology 165:6880.
Accession # |
P29460 (IL-12p40), P29459 (IL-12p35) |
Alternate Names |
Human IL12; hIL-12, recombinant IL12, interleukin 12 |
Source |
Human embryonic kidney cell, HEK293-derived human IL12 protein |
Protein sequence |
IL-12 p40 (Ile23-Ser328), IL-12 p35 (Arg23-Ser219) |
M.Wt |
22.5 kDa + 34.7 kDa |
Appearance |
Solution protein. |
Stability & Storage |
Avoid repeated freeze-thaw cycles. It is recommended that the protein be aliquoted for optimal storage. 12 months from date of receipt, -20 to -70 °C as supplied. |
Concentration |
0. 2 mg/mL |
Formulation |
Dissolved in sterile PBS buffer. |
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers. |
Biological Activity |
Measured in a cell proliferation assay using PHA-stimulated human T lymphoblasts. The EC50 for this effect is 4-40 pg/mL |
Shipping Condition |
Shipping with dry ice. |
Handling |
Centrifuge the vial prior to opening. |
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95%, determined by SDS-PAGE.
- Datasheet
Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.